| Literature DB >> 34677453 |
Meijia He1, Yajing Yang1, Zhuling Shao1, Junyan Zhang1, Changning Feng1, Lei Wang1, Wenjun Mao1,2.
Abstract
Marine macroalgae are efficient producers of sulfated polysaccharides. The algal sulfated polysaccharides possess diverse bioactivities and peculiar chemical structures, and represent a great potential source to be explored. In the present study, a heparinoid-active sulfated polysaccharide was isolated from the green alga Cladophora oligoclada. Results of chemical and spectroscopic analyses indicated that the sulfated polysaccharide was composed of →6)-β-d-Galp-(1→, β-d-Galp-(1→, →6)-α-d-Glcp-(1→ and →3)-β-d-Galp-(1→ units with sulfate esters at C-2/C-4 of →6)-β-d-Galp-(1→, C-6 of →3)-β-d-Galp-(1→ and C-3 of →6)-α-d-Glcp-(1→ units. The branches consisting of β-d-Galp-(1→ and →6)-β-d-Galp-(1→ units were located in C-3 of →6)-β-d-Galp-(1→ units. The sulfated polysaccharide exhibited potent anticoagulant activity in vitro and in vivo as evaluated by activated partial thromboplastin time (APTT), thrombin time, and the fibrinogen level. For the APTT, the signal for clotting time was more than 200 s at 100 μg/mL in vitro and at 15 mg/kg in vivo. The obvious thrombolytic activity of the sulfated polysaccharide in vitro was also found. The mechanism analysis of anticoagulant action demonstrated that the sulfated polysaccharide significantly inhibited the activities of all intrinsic coagulation factors, which were less than 1.0% at 50 μg/mL, but selectively inhibited common coagulation factors. Furthermore, the sulfated polysaccharide strongly stimulated the inhibition of thrombin by potentiating antithrombin-III (AT-III) or heparin cofactor-II, and it also largely promoted the inhibition of factor Xa mediated by AT-III. These results revealed that the sulfated polysaccharide from C. oligoclada had potential to become an anticoagulant agent for prevention and therapy of thrombotic diseases.Entities:
Keywords: action mechanism; alga; anticoagulant property; structure; sulfated polysaccharide
Mesh:
Substances:
Year: 2021 PMID: 34677453 PMCID: PMC8540071 DOI: 10.3390/md19100554
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1HPGPC and HPLC chromatograms and IR spectrum of OCSH4. (A) HPGPC chromatogram of OCSH4 on a Shodex OHpak SB-804 HQ column and the standard curve of molecular weight. (B) HPLC chromatogram for the monosaccharide composition analysis of OCSH4 (Man: d-mannose, GlcN: d-glucosamine, Rha: l-rhamnose, GlcA: d-glucuronic acid, GalA: d-galacturonic acid, Glc: d-glucose, Gal: d-galactose, Xyl: d-xylose, Ara: l-arabinose, Fuc: l-fucose). (C) HPLC chromatogram for the sugar configuration determination of OCSH4; and (D) IR spectrum of OCSH4.
Results of methylation analyses of OCSH4 and dsOCSH4.
| Methylated Alditol Acetate | Molar Percent Ratio | Linkage Pattern | |
|---|---|---|---|
| OCSH4 | dsOCSH4 | ||
| 1,5-Di- | 10.91 | 11.06 | Gal |
| 1,3,5-Tri- | -- | 13.25 | →3)-Gal |
| 1,5,6-Tri- | -- | 10.31 | →6)-Glc |
| 1,5,6-Tri- | 37.03 | 52.32 | →6)-Gal |
| 1,4,5,6-Tetra- | 10.44 | -- | →4,6)-Gal |
| 1,3,5,6-Tetra- | 10.33 | -- | →3,6)-Glc |
| 1,3,5,6-Tetra- | 26.26 | 13.06 | →3,6)-Gal |
| 1,2,5,6-Tetra- | 5.03 | -- | →2,6)-Gal |
Figure 2NMR spectra of dsOCSH4. A-E: →6)-α-d-Glcp-(1→, →3)-β-d-Galp-(1→, β-d-Galp-(1→, →3,6)-β-d-Galp-(1→ and →6)-β-d-Galp-(1→. Glcp: glucopyranose, Galp: galactopyranose.
Signal assignments of NMR spectra of dsOCSH4.
| Sugar Residues | Chemical Shifts (ppm) | |||||
|---|---|---|---|---|---|---|
| H1/C1 | H2/C2 | H3/C3 | H4/C4 | H5/C5 | H6/C6 | |
| A→6)- | 5.01/99.43 | 3.86/71.10 | 3.80/73.59 | 3.73/70.48 | 3.71/71.63 | 4.00;4.09/69.59 |
| B→3)- | 4.73/104.99 | 3.80/71.19 | 3.96/75.63 | 4.08/70.30 | 3.73/73.59 | 3.80;3.86/62.05 |
| C | 4.61/104.09 | 3.71/71.72 | 3.69/71.89 | 4.00/70.39 | 3.96/73.59 | 3.86/62.14 |
| D→3,6)- | 4.53/104.99 | 3.56/71.01 | 3.74/76.06 | 3.72/71.01 | 3.80/73.68 | 3.96/69.68 |
| E→6)- | 4.51/104.42 | 3.73/71.89 | 3.58/71.63 | 3.99/70.58 | 3.97/73.50 | 3.96/69.68 |
Spectra were performed on an Agilent DD2 500M NMR spectrometer. Chemical shifts are referenced to internal acetone at 2.225 ppm for 1H and 31.07 ppm for 13C. Glcp: glucopyranose, Galp: galactopyranose.
Figure 3Structures of the major disaccharides in dsOCSH4.
Signal assignments of NMR spectra of OCSH4.
| Sugar Residues | Chemical Shifts (ppm) | |||||
|---|---|---|---|---|---|---|
| H1/C1 | H2/C2 | H3/C3 | H4/C4 | H5/C5 | H6/C6 | |
| A→6)- | 5.09/99.57 | 3.99/70.31 | 4.48/79.55 | 3.74/72.26 | 3.72/72.31 | 4.94;4.14/70.31 |
| B→6)- | 4.76/103.03 | 4.40/79.64 | 3.69/70.48 | 3.99/70.31 | 3.95/74.03 | 3.94/70.40 |
| C | 4.62/104.30 | 3.72/73.95 | 3.69/71.32 | 3.98/70.40 | 3.96/74.63 | 3.80/62.43 |
| D→3)- | 4.60/104.30 | 3.69/72.26 | 3.73/77.34 | 4.05/70.31 | 3.57/72.26 | 4.23/72.26 |
| E→6)- | 4.59/104.30 | 3.57/73.87 | 3.59/72.26 | 4.43/77.34 | 3.99/74.03 | 3.94/70.23 |
| F→3,6)- | 4.53/104.88 | 3.56/72.18 | 3.73/77.34 | 3.57/71.32 | 3.59/73.95 | 3.95/70.23 |
| G→6)- | 4.50/104.88 | 3.72/72.26 | 3.57/72.26 | 3.99/70.31 | 3.95/74.03 | 3.94/70.40 |
Spectra were performed on an Agilent DD2 500M NMR spectrometer. Chemical shifts are referenced to internal acetone at 2.225 ppm for 1H and 31.07 ppm for 13C. Glcp: glucopyranose, Galp: galactopyranose.
Figure 4Anticoagulant activities of OCSH4 and dsOCSH4 in vitro. (A) APTT; (B) TT; (C) PT; and (D) FIB. Values were mean ± SD (n = 3).
Result of anticoagulant activity assay of OCSH4 in vivo.
| Samples | Concentration | Clotting Time a (s) | ||
|---|---|---|---|---|
| APTT | TT | PT | ||
| OCSH4 | 0 | 18.2 ± 1.7 | 20.3 ± 0.9 | 15.3 ± 0.1 |
| 1 | 39.7 ± 3.3 ** | 35.5 ± 2.6 ** | 15.2 ± 0.7 | |
| 3.75 | 88.9 ± 2.7 ** | 42.1 ± 1.2 ** | 15.6 ± 0.4 | |
| 7.5 | 129.6 ± 4.5 **## | 60.4 ± 2.7 ** | 15.7 ± 0.9 | |
| 15 | >200 **## | 79.7 ± 3.4 **# | 15.7 ± 1.1 | |
| Heparin | 0 | 18.2 ± 1.7 | 20.3 ± 0.9 | 15.3 ± 0.1 |
| 1 | 106.4 ± 3.7 ** | 60.2 ± 0.8 ** | 55.3 ± 1.7 | |
a Values were mean ± SD (n = 8). Significance: ** p < 0.01 vs. the control group; # p < 0.05, ## p < 0.01 vs. the heparin group.
Inhibition of coagulation factors, II, V, X, VIII, IX, XI and XII by OCSH4.
| Coagulation Factors | Activities of Coagulation Factors (%) a | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| OCSH4 (μg/mL) | Heparin (μg/mL) | ||||||||
| 0 | 5 | 10 | 25 | 50 | 0 | 0.1 | 1 | 5 | |
| II | 101.8 ± 1.9 | 97.2 ± 2.9 | 98.4 ± 1.2 | 87.2 ± 1.2 | 63.7 ± 2.0 | 100.0 ± 0.9 | 90.7 ± 2.6 | 86.4 ± 2.1 | 75.2 ± 1.1 |
| V | 101.2 ± 2.21 | 98.7 ± 3.4 | 69.6 ± 1.8 | 35.5 ± 4.0 | 18.3 ± 1.1 | 99.9 ± 3.2 | 69.3 ± 4.7 | 41.6 ± 2.9 | <1.0 |
| VII | 100.0 ± 2.1 | 64.7 ± 2.2 | 41.4 ± 1.7 | 6.8 ± 4.0 | <1.0 | 100.4 ± 1.8 | 50.2 ± 2.7 | 1.4 ± 3.3 | <1.0 |
| IX | 100.0 ± 1.0 | 79.0 ± 3.2 | 53.5 ± 0.7 | 12.1 ± 0.9 | <1.0 | 100.9 ± 0.3 | 55.9 ± 0.7 | 2.3 ± 1.6 | <1.0 |
| X | 99.8 ± 1.1 | 97.1 ± 0.8 | 95.2 ± 1.5 | 94.4 ± 2.0 | 94.2 ± 2.6 | 100.5 ± 1.3 | 97.8 ± 3.1 | 95.2 ± 0.5 | 82.1 ± 3.3 |
| XI | 100.0 ± 0.2 | 72.5 ± 1.4 | 47.7 ± 0.4 | 9.1 ± 1.2 | <1.0 | 100.7 ± 1.2 | 42.0 ± 1.9 | 9.2 ± 1.1 | <1.0 |
| XII | 102.0 ± 2.4 | 41.3 ± 1.2 | 27.0 ± 0.3 | 7.9 ± 1.6 | <1.0 | 101.2 ± 1.9 | 59.7 ± 0.5 | 1.3 ± 0.2 | <1.0 |
a Values were mean ± SD (n = 3). The activities of coagulation factors were estimated by reference to calibration curves made by serial dilutions of standard human plasma. The standard human plasma with a dilution ratio of 1:5 (plasma/imidazole buffer, v/v) was used as a control.
Figure 5Inhibition of OCSH4 on HC-II/AT-III-dependent thrombin or factor Xa activity. Values were mean ± SD (n = 3). (A) Thrombin activity with or without of HC-II; (B) thrombin activity with or without AT-III; and (C) factor Xa activity with or without AT-III.
Figure 6Thrombolytic activity in vitro of OCSH4. Values were mean ± SD (n = 10). Significance: ** p < 0.01 vs. the control group, ## p < 0.01 vs. the model group.